Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Applied Digital Corporation (APLD) vs Ascendis Pharma A/S (ASND) Price & Performance

Applied Digital CorporationTrade
Ascendis Pharma A/STrade

Price performance (Past 24H)

Key statistics

Applied Digital Corporation vs Ascendis Pharma A/S — how do they compare? Applied Digital Corporation trades at $31.04 (market cap $8.55B), while Ascendis Pharma A/S trades at $257 (market cap $16.67B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Applied Digital Corporation nearer its low. Which is the better fit depends on your goals.

APLDASND
Market Cap
$8.55B$16.67B
Sector
TechnologyHealth
52-Week High
$49.65$277.18
52-Week Low
$13.89$189.74
Enterprise Value
$12.06B$17.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Applied Digital Corporation

APLD trades at $31.15, up 7.19% today, with a neutral technical signal and bearish moving averages. The company reported a net loss of $231.07M in 2025 despite revenue growth, but has a $36B contracted AI infrastructure pipeline. Analyst consensus is unanimously bullish with a $72.36 price target, though recent insider selling and negative cash flow from operations highlight near-term risks.

The outlook hinges on execution of its AI data center build-out, with projected revenue surging to $611M in 2026. Investment opportunity lies in the massive contracted backlog, but risks include high debt, negative margins, and reliance on capital markets for funding expansion.

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.

ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Applied Digital Corporation

Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.

Read more on APLD

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND